RxDoctor Payments Data

Richard Bernstein, MD

Pulmonary Disease · Hershey, PANPI 1245498831

Payments from drug & device makers

$98,248in general payments, 2019–2025

Across 30 payments — averaging $3274.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$53K
  • Mallinckrodt Enterprises LLC$45K
  • GSK$101
  • AstraZeneca$23
  • Insmed, Inc.$16

What the payments were for

  • Food & beverage$10172%
  • Education$3928%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$98,248 in reported general payments places this provider in the 85th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$50,588
Medicare patients
466
Services billed
982

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$27,489
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$23,013
Spiriva HandihalerTiotropium Bromide27$18,400
Spiriva RespimatTiotropium Bromide18$9,788
Breo ElliptaFluticasone/Vilanterol15$8,781
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$7,599
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$7,324
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate28$7,003
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,612
Incruse ElliptaUmeclidinium Bromide19$6,563
Tiotropium Bromide14$5,410
Mycophenolate Mofetil39$4,573
BreynaBudesonide/Formoterol Fumarate14$3,413
Albuterol Sulfate HfaAlbuterol Sulfate97$3,153
Roflumilast15$2,726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$101$65,845106 claims
AstraZenecaBreztri Aerosphere$23$6,61211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Hershey

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →